AVEO Pharmaceuticals Total Assets 2011-2026 | AVEO

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets AVEO Pharmaceuticals

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
105 M	66.9 M	50.6 M	27.9 M	50.2 M	27.3 M	40.5 M	70.7 M	146 M	207 M	295 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
295 M	27.3 M	98.9 M

Quarterly Total Assets AVEO Pharmaceuticals

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	101 M	-	98.2 M	105 M	109 M	113 M	127 M	66.9 M	66.9 M	66.9 M	66.9 M	50.6 M	50.6 M	50.6 M	50.6 M	27.9 M	27.9 M	27.9 M	27.9 M	50.2 M	50.2 M	50.2 M	50.2 M	27.3 M	27.3 M	27.3 M	27.3 M	40.5 M	40.5 M	40.5 M	40.5 M	70.7 M	70.7 M	70.7 M	70.7 M	146 M	146 M	146 M	146 M	207 M	207 M	207 M	207 M	295 M	295 M	295 M	295 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
295 M	27.3 M	99.7 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Processa Pharmaceuticals PCSA	7.81 M	$ 2.3	-1.29 %	$ 3.01 M	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	62.2 M	-	10.36 %	$ 9.8 M	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Ascendis Pharma A/S ASND	1.3 B	$ 220.9	2.49 %	$ 5 B	Danmark
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Amphastar Pharmaceuticals AMPH	1.63 B	$ 19.57	1.77 %	$ 915 M	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Phathom Pharmaceuticals PHAT	259 M	$ 10.47	4.08 %	$ 763 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
AgeX Therapeutics AGE	12 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Atreca BCEL	155 M	-	-11.76 %	$ 5.79 M	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
BeiGene, Ltd. BGNE	8.19 B	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	619 M	-	-	$ 546 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Cara Therapeutics CARA	126 M	-	-3.03 %	$ 260 M	USA
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Pliant Therapeutics PLRX	225 M	$ 1.31	2.34 %	$ 80.4 M	USA
PMV Pharmaceuticals PMVP	117 M	$ 1.37	-1.44 %	$ 72 M	USA
Avenue Therapeutics ATXI	2.67 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	783 M	$ 1.33	0.76 %	$ 339 M	Britain
Corbus Pharmaceuticals Holdings CRBP	168 M	$ 8.31	1.59 %	$ 111 M	USA
CRISPR Therapeutics AG CRSP	2.27 B	$ 47.09	1.42 %	$ 4.23 B	Schweiz
Cyclacel Pharmaceuticals CYCC	4.09 M	-	-5.98 %	$ 34.1 M	USA
ChemoCentryx CCXI	426 M	-	-	$ 3.74 B	USA
Prelude Therapeutics Incorporated PRLD	141 M	$ 3.26	4.49 %	$ 251 M	USA
Dynavax Technologies Corporation DVAX	986 M	-	-	$ 2.02 B	USA
ProQR Therapeutics N.V. PRQR	113 M	$ 1.58	6.04 %	$ 99.5 M	Niderland
BioDelivery Sciences International BDSI	325 M	-	-4.8 %	$ 255 M	USA
Enochian Biosciences ENOB	8.23 M	-	-	$ 40.5 M	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Palatin Technologies PTN	3.27 M	$ 21.0	5.79 %	$ 19.5 M	USA
Bellerophon Therapeutics BLPH	7.94 M	-	-74.18 %	$ 955 K	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Pulmatrix PULM	4.14 M	$ 2.12	-1.4 %	$ 7.74 M	USA
Arbutus Biopharma Corporation ABUS	94.6 M	$ 4.53	5.1 %	$ 868 M	Canada
Homology Medicines FIXX	61.8 M	-	0.77 %	$ 53.4 M	USA